Amgen threatens to steal show at ASCO 2019 with KRAS data

Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen (Nasdaq: AMGN) is definitely a contender at this year's event.

The US biotech’s share price was up 4% after the morning’s trading on Monday, when it presented the first results from its Phase I study investigating AMG 510, the first KRASG12C inhibitor to reach the clinical stage.

"KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago"In the trial, 35 patients were enrolled with various tumor types, and out of 10 with non-small cell lung cancer, five experienced a partial response (PR), and another four had stable disease. One patient with PR improved further to a complete response of the target lesions at week 18, post data cut-off.